Bahrain now second nation to grant Pfizer shot emergency use

December 05, 2020 09:39 am | Updated 09:39 am IST - Dubai

Bahrain says it has become the second nation in the world to grant an emergency-use authorisation for the coronavirus vaccine made by Pfizer and BioNTech. It did not say how may vaccines it has purchased, nor when vaccinations would begin.

Bahrain says it has become the second nation in the world to grant an emergency-use authorisation for the coronavirus vaccine made by Pfizer and BioNTech. It did not say how may vaccines it has purchased, nor when vaccinations would begin.

The island kingdom of Bahrain said on Friday it has become the second nation in the world to grant an emergency-use authorisation for the coronavirus vaccine made by Pfizer and its German partner BioNTech.

The state-run Bahrain News Agency made the announcement on Friday night, following an earlier announcement by the United Kingdom on Wednesday, making Britain the first in the world .

The confirmation of approval by the National Health Regulatory Authority of the kingdom of Bahrain followed thorough analysis and review undertaken by the authority of all available data, the kingdom said on its state-run Bahrain News Agency.

Bahrain did not say how may vaccines it has purchased, nor when vaccinations would begin. It did not immediately respond to questions from The Associated Press .

Pfizer later told the AP that the details of its sales agreement with Bahrain, including the timing of delivery and the volume of doses, was confidential and declined to comment.

“We have developed detailed logistical plans and tools to support effective vaccine transport, storage and continuous temperature monitoring,” Pfizer said. “Our distribution is built on a flexible just in time system which will ship the frozen vials to the point of vaccination.”

The immediate challenge for Bahrain would be the conditions in which the vaccine must be kept. They must be stored and shipped at ultra-cold temperatures of around minus 70 degrees Celsius. Bahrain is a Mideast nation that regularly sees temperatures in the summer of around 40 degrees Celsius with high humidity.

Bahrain does have a state-owned carrier, Gulf Air, that it could use to transport the vaccines. In the nearby United Arab Emirates, the Dubai-based long-haul carrier Emirates has already said it is preparing its facilities to distribute vaccines at ultra-cold temperatures.

The vaccine also requires two doses be given three weeks apart.

Bahrain had already granted emergency-use authorisation for a Chinese vaccine made by Sinopharm and has inoculate some 6,000 people with it. That vaccine, an inactivated shot made by growing the whole virus in a lab and then killing it, also is in use in the UAE.

“The approval of the Pfizer/BioNTech vaccine will add a further important layer to the kingdom’s national COVID-19 response, which has strongly prioritised protecting the health of all citizens and residents during the pandemic,” said Dr. Mariam al-Jalahma, the CEO of Bahrain’s National Health Regulatory Authority.

BioNTech, which owns the vaccine, said it has so far signed deals to supply 570 million doses worldwide in 2021, with options to deliver 600 million more. It hopes to supply at least 1.3 billion in 2021.

With a population of 1.6 million, Bahrain has reported more than 87,000 cases and 341 deaths, according to the government. Over 85,000 people have recovered from the COVID-19 illness that is caused by the virus.

The Bahraini government says it has conducted over 2 million coronavirus tests across the island. It initially blamed its higher per-capita infection rate on that.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.